RecruitingPhase 3NCT07309055

A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd

Enrollment

201 participants

Start Date

Mar 21, 2026

Study Type

INTERVENTIONAL

Conditions

Adolescents With Moderate-to-severe Atopic Dermatitis

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.

Eligibility

Min Age: 12 YearsMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SHR-1819 Injection and a drug called SHR-1819 Injection Placebo for people with adolescents with moderate-to-severe atopic dermatitis. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 12 Years to 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSHR-1819 Injection

SHR-1819 injection.

DRUGSHR-1819 Injection Placebo

SHR-1819 injection placebo.

Locations(2)

The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, China

Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07309055